News | Leads Implantable Devices | May 13, 2019

BioTrace Medical's Tempo Lead Obtains CE Mark for Temporary Intracardiac Pacing

Temporary pacing lead designed to reduce intraprocedural complications following TAVR and TMVR

BioTrace Medical's Tempo Lead Obtains CE Mark for Temporary Intracardiac Pacing

May 13, 2019 — BioTrace Medical Inc. announced the company’s Tempo Lead has obtained CE Mark certification in Europe for use in cardiac procedures requiring temporary intracardiac pacing.

BioTrace Medical’s Tempo Temporary Pacing Lead is designed for safer, more secure and stable pacing to reduce intraprocedural complications, including perforation and valve embolization. In addition, the Tempo Lead allows patients to ambulate sooner after procedures such as transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve replacement (TMVR), accelerating recovery times, and enabling patient transfer directly to a step-down or telemetry unit instead of an ICU or CCU.

Cleared by the U.S. Food and Drug Administration (FDA) in October 2016, the Tempo Lead’s design, featuring novel retractable stabilizer loops and a soft tip, mitigates the risks of dislodgment and perforation and ensures stability during rapid pacing.

In a U.S. multi-center retrospective study1 of 269 patients led by Columbia University Medical Center and presented at the American College of Cardiology’s Annual Scientific Session in 2018, the Tempo Lead was successfully placed in 98.1 percent of the cases with no cardiac perforations, pericardial effusions or sustained device-related arrhythmias, and only a 0.8 percent loss of pace capture. The Tempo lead was left in place post-procedure in 71.6 percent of the cases, of which 84.1 percent mobilized out of bed while maintaining stable pace capture with no dislodgment. The study confirmed the Tempo Lead is safe and effective for temporary cardiac pacing, provides stable peri- and post-procedural pacing support, and facilitates post-procedure ambulation, which can safely allow direct transfer to step-down or telemetry units with no ICU time required, reducing length of stay.2

In addition, the Tempo Lead allows watchful waiting after procedures, potentially avoiding permanent pacemaker implantation in patients with transient conduction disturbances that may resolve on their own with time. The European Society of Cardiology cardiac pacing guidelines recommend a seven-day period of clinical observation to assess the type and significance of disturbances before permanent pacemaker implantation,3 a period of time in which the need for safe and stable temporary pacing allowing ambulation is even more important. These benefits are increasingly significant as TAVR procedures expand to intermediate and low-risk patients.

The design of conventional temporary pacing leads can cause serious complications, including perforation of the heart wall, which may lead to potentially life-threatening compression of the heart. Additionally, conventional leads can easily dislodge from the heart, often resulting in loss of pacing with serious consequences for the patient. As a result, patients are routinely limited to bed rest for the duration of temporary pacing, delaying ambulation and thereby increasing length of stay in costly hospital units such as intensive care.

For more information: www.biotracemedical.com

References

1. Nazif, T et al. Analysis of the Initial United States Experience with the BioTrace Tempo Temporary Pacing Lead in Transcatheter Aortic Valve Replacement (TAVR) and Other Cardiac Procedures, Journal of the American College of Cardiology, Volume 71, Issue 11, Supplement, 2018, Page A1285, ISSN 0735-1097, https://doi.org/10.1016/S0735-1097(18)31826-6

2. Yakubov SR. TCT 2017: How to Manage Conduction Abnormalities and Pacemaker Implantation (temporary and permanent) After TAVR. November 1, 2017, https://www.tctmd.com/videos/how-to%C2%85-manage-conduction-abnormalities-and-pacemaker-implantation-temporary-and-permanent-after-tavr.f1c14ee9364243e0abd8e604545cda07

3. Michele Brignole et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy, European Heart Journal (2013) 34, 2281–2329 doi:10.1093/eurheartj/eht150

Related Content

News | Cath Lab

October 6, 2021 — Boston Scientific Corp. announced it entered into a definitive agreement to acquire Baylis Medical ...

Home October 06, 2021
Home
News | Cath Lab

September 21, 2021 — Medtronic is recalling its Pipeline Flex Embolization Device and Pipeline Flex Embolization Device ...

Home September 21, 2021
Home
Feature | Cath Lab | By Aaron Detate and Lars Thording

In the electrophysiology (EP) lab, hundreds of thousands of used devices are sent to reprocessors every year to get ...

Home September 14, 2021
Home
News | Cath Lab

July 22, 2021 — Medis Medical Imaging is partnering with CORRIB Core Lab and Sinomed in randomized clinical trial of ...

Home July 22, 2021
Home
News | Cath Lab

July 13, 2021 — East End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company ...

Home July 14, 2021
Home
Feature | Cath Lab | By Dave Fornell, Editor

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal ...

Home May 14, 2021
Home
News | Cath Lab

May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has ...

Home May 12, 2021
Home
Feature | Cath Lab | By Dave Fornell, Editor

April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from the ...

Home May 06, 2021
Home
Videos | Cath Lab

Ashwin Nathan M.D., a cardiology fellow in the division of Cardiovascular Medicine at the Hospital of the University of ...

Home May 05, 2021
Home
News | Cath Lab

May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for stable ...

Home May 03, 2021
Home
Subscribe Now